Search Options Stock News and Analysis from Schaeffer's

Bluebird Stock Upgraded Ahead of Anticipated FDA Approval

https://www.schaeffersresearch.com/content/news/2023/12/08/bluebird-stock-upgraded-ahead-of-anticipated-fda-approval

12/8/2023 10:47 AM

Bluebird Bio Inc (NASDAQ:BLUE) stock is enjoying a boost today, after an upgrade from Morgan Stanley to "equal-weight" from "underweight," with a price-target hike to $7.00 from $3.00. The firm antic...

Bluebird Stock Reverses Gains, Down Nearly 12%

https://www.schaeffersresearch.com/content/news/2022/09/19/bluebird-stock-reverses-gains-down-nearly-12

9/19/2022 10:32 AM

Bluebird Bio Inc (NASDAQ:BLUE) is in the spotlight today, after the U.S. Food and Drug Administration (FDA) approved SKYSONA, its gene therapy for the treatment of Cerebral Adrenoleukodystrophy (CALD)...

BLUE Brings Back Treatment From Marketing Suspension

https://www.schaeffersresearch.com/content/news/2021/07/09/blue-brings-back-treatment-from-marketing-suspension

7/9/2021 10:36 AM

The shares of bluebird bio Inc (NASDAQ:BLUE) are higher today, on news that the biotech company is lifting its voluntary marketing suspension of its gene therapy treatment, Zynteglo. The drug, which ...

BLUE, BB, BNTX Stocks Climbing on Bull Notes

https://www.schaeffersresearch.com/content/news/2019/11/04/blue-bb-bntx-stocks-climbing-on-bull-notes

11/4/2019 2:42 PM

The U.S. stock market is soaring once more, with all three benchmarks nabbing new record highs. Among specific stocks making notable moves higher are gene therapy specialist bluebird bio Inc (NASDAQ...

bluebird bio Ready to Rally on Regeneron Investment

https://www.schaeffersresearch.com/content/news/2018/08/06/bluebird-bio-ready-to-rally-on-regeneron-investment

8/6/2018 9:16 AM

Massachusetts-based biotech company bluebird bio (NASDAQ:BLUE) today announced a collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN) to jointly develop new cell therapies for cancer. Under the...

PEOPLE ALSO SEARCH FOR